Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
•
COPD
Will you incorporate ensifentrine in the treatment regimen of patients with COPD on baseline dual or triple inhaler therapy?
Related Questions
Do you use bronchodilator response to distinguish between asthma, COPD, or asthma-COPD overlap?
Have you implemented the Rome proposal for COPD exacerbations?
What patient factors prompt you to consider starting dupilumab in patients with COPD?
Do you check blood eosinophil counts in patients with COPD exacerbations to help guide therapy decisions?
Will you use FeNO testing in all COPD patients to determine whether they are candidates for therapy with dupilumab?
Did the low rate of COPD exacerbations in the BOREAS cohort overall confound the results of the study?
Are the results of the BOREAS trial generalizable to non-white populations?
How do you factor smoking history into biologic selection for asthma since the clinical trials generally excluded these patients?
Can recurrent bilateral nasal polyps be attributed to untreated ABPA?
What is your approach to de-escalation of asthma therapy if patients have remained clinically stable on triple inhaler therapy and a biologic agent?
